RCT: Atezolizumab with Chemotherapy Extends Progression-Free Survival in dMMR Advanced Endometrial Cancer – Lancet Oncol

Study Design and Population: The AtTEnd trial is a randomized, double-blind, placebo-controlled phase 3 study conducted in 89 hospitals across 11 countries. It enrolled 551 patients with advanced or recurrent endometrial carcinoma or carcinosarcoma, all of whom had not received prior systemic chemotherapy for recurrence.

Main Findings: The addition of atezolizumab to chemotherapy was associated with an improvement in progression-free survival, particularly in patients with mismatch repair-deficient (dMMR) tumors. In the overall population, progression-free survival and overall survival also showed positive trends.

Implications for Practice: The study suggests that atezolizumab may offer benefits when added to standard chemotherapy in patients with dMMR advanced or recurrent endometrial carcinoma, warranting further investigation as a potential first-line treatment option.

Reference: Colombo, N. et al. (2024). Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 24(8), 334-346. DOI: https://doi.org/10.1016/S1470-2045(24)00334-6.